Product Description
Formoterol oral inhalation is used to control wheezing, shortness of breath, and chest tightness caused by chronic obstructive pulmonary disease (COPD; a group of lung diseases that includes chronic bronchitis and emphysema). Formoterol is in a class of medications called long-acting beta agonists (LABAs). (Sourced from: https://medlineplus.gov/druginfo/meds/a602023.html)
Mechanisms of Action: LAB Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Asthma | Bronchitis | Bronchitis, Chronic | Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema | Spasm | Asthma | Asthma, Exercise-Induced | Chronic Obstructive Pulmonary Disease | Spasm | Asthma | Spasm | Asthma | Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease
Known Adverse Events: Dizziness | Insomnia | Nasopharyngitis | Pharyngitis | Diarrhea | Back Pain | Chest Pain | Pain Unspecified | Tremor | Tonsillitis | Pruritus | Respiratory Tract Infections | Muscle Cramp | Asthma | Bronchitis | Dysphonia | Chronic Obstructive Pulmonary Disease | Sinusitis | Dyspnea | Headache | Spasm | Candidiasis | Candidiasis, Oral | Pneumonia | Influenza, Human
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Italy, Japan, Korea, Malaysia, Mexico, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 22
Highest Development Phases
Phase 3: Asthma|Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| D5989C00001 THARROS | P3 |
Unknown Status |
Chronic Obstructive Pulmonary Disease |
2028-03-07 |
|
| TRIPLAR | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2027-11-30 |
|
| FORASMA | P3 |
Not yet recruiting |
Asthma |
2026-05-30 |
78% |
| FORASMA | P3 |
Not yet recruiting |
Asthma |
2026-05-30 |
78% |
| TRITON | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2026-01-01 |